

Basil Sharrack

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8333151/publications.pdf>

Version: 2024-02-01

65
papers

1,778
citations

377584

21
h-index

325983

40
g-index

67
all docs

67
docs citations

67
times ranked

2856
citing authors

#	ARTICLE	IF	CITATIONS
1	The impact of smoking cessation on multiple sclerosis disease progression. <i>Brain</i> , 2022, 145, 1368-1378.	3.7	16
2	The four self-efficacy trajectories among people with multiple sclerosis: Clinical associations and implications. <i>Journal of the Neurological Sciences</i> , 2022, 436, 120188.	0.3	3
3	High-intensity interval training in people with mild multiple sclerosis: a mixed-methods feasibility study. <i>International Journal of Therapy and Rehabilitation</i> , 2022, 29, 1-14.	0.1	1
4	Autologous haematopoietic stem cell transplantation for refractory stiff-person syndrome: the UK experience. <i>Journal of Neurology</i> , 2021, 268, 265-275.	1.8	27
5	A Multifactorial Model of Multiple Sclerosis Gait and Its Changes Across Different Disability Levels. <i>IEEE Transactions on Biomedical Engineering</i> , 2021, 68, 3196-3204.	2.5	10
6	The Cost Effectiveness of Immunoglobulin vs. Hematopoietic Stem Cell Transplantation for CIDP. <i>Frontiers in Neurology</i> , 2021, 12, 645263.	1.1	11
7	Tissue distribution and cellular localization of gold nanocarriers with bound oligonucleotides. <i>Nanomedicine</i> , 2021, 16, 709-720.	1.7	3
8	Quality of life in multiple sclerosis is dominated by fatigue, disability and self-efficacy. <i>Journal of the Neurological Sciences</i> , 2021, 426, 117437.	0.3	19
9	Endothelial-Derived Extracellular Vesicles Induce Cerebrovascular Dysfunction in Inflammation. <i>Pharmaceutics</i> , 2021, 13, 1525.	2.0	15
10	Walking on common ground: a cross-disciplinary scoping review on the clinical utility of digital mobility outcomes. <i>Npj Digital Medicine</i> , 2021, 4, 149.	5.7	54
11	The utility of whole-exome sequencing in accurate diagnosis of neuromuscular disorders in consanguineous families in Jordan. <i>Clinica Chimica Acta</i> , 2021, 523, 330-338.	0.5	5
12	Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110576.	1.5	5
13	Technical validation of real-world monitoring of gait: a multicentric observational study. <i>BMJ Open</i> , 2021, 11, e050785.	0.8	56
14	Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE). <i>Bone Marrow Transplantation</i> , 2020, 55, 283-306.	1.3	128
15	Health economics and patient outcomes of hematopoietic stem cell transplantation versus disease-modifying therapies for relapsing remitting multiple sclerosis in the United States of America. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 45, 102404.	0.9	14
16	MS-SMART study: systematic sampling bias concerns – Authors' reply. <i>Lancet Neurology</i> , The, 2020, 19, 479-480.	4.9	0
17	Generation and characterization of induced pluripotent stem cell (iPSC) line (JUCTCi002-A) from a patient with ataxia with oculomotor apraxia type 1 (AOA1) harboring a homozygous mutation in the APTX gene. <i>Stem Cell Research</i> , 2020, 48, 101925.	0.3	3
18	Identification of APTX disease-causing mutation in two unrelated Jordanian families with cerebellar ataxia and sensitivity to DNA damaging agents. <i>PLoS ONE</i> , 2020, 15, e0236808.	1.1	5

#	ARTICLE	IF	CITATIONS
19	Gold nanocarriers for transport of oligonucleotides across brain endothelial cells. PLoS ONE, 2020, 15, e0236611.	1.1	17
20	Autologous hematopoietic stem-cell transplantation in neurological disorders: current approach and future directions. Expert Review of Neurotherapeutics, 2020, 20, 1299-1313.	1.4	7
21	A Case of Multiple Sclerosisâ€™Like Relapsing Remitting Encephalomyelitis Following Allogeneic Hematopoietic Stem Cell Transplantation and a Review of the Published Literature. Frontiers in Immunology, 2020, 11, 668.	2.2	8
22	Wearable sensors can reliably quantify gait alterations associated with disability in people with progressive multiple sclerosis in a clinical setting. Journal of Neurology, 2020, 267, 2897-2909.	1.8	37
23	Hematopoietic stem cell transplantation for chronic inflammatory demyelinating polyradiculoneuropathy. Journal of Neurology, 2020, 267, 3378-3391.	1.8	28
24	Cerebrospinal fluid dynamics modulation by diet and cytokines in rats. Fluids and Barriers of the CNS, 2020, 17, 10.	2.4	17
25	Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial. Lancet Neurology, The, 2020, 19, 214-225.	4.9	81
26	Is a Wearable Sensor-Based Characterisation of Gait Robust Enough to Overcome Differences Between Measurement Protocols? A Multi-Centric Pragmatic Study in Patients with Multiple Sclerosis. Sensors, 2020, 20, 79.	2.1	17
27	Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis: the MS-SMART four-arm RCT. Efficacy and Mechanism Evaluation, 2020, 7, 1-72.	0.9	11
28	Title is missing!. , 2020, 15, e0236808.		0
29	Title is missing!. , 2020, 15, e0236808.		0
30	Title is missing!. , 2020, 15, e0236808.		0
31	Title is missing!. , 2020, 15, e0236808.		0
32	Gold nanocarriers for transport of oligonucleotides across brain endothelial cells. , 2020, 15, e0236611.		0
33	Gold nanocarriers for transport of oligonucleotides across brain endothelial cells. , 2020, 15, e0236611.		0
34	Gold nanocarriers for transport of oligonucleotides across brain endothelial cells. , 2020, 15, e0236611.		0
35	Gold nanocarriers for transport of oligonucleotides across brain endothelial cells. , 2020, 15, e0236611.		0
36	Do Optic Canal Dimensions Measured on CT Influence the Degree of Papilloedema and Visual Dysfunction in Idiopathic Intracranial Hypertension?. Neuro-Ophthalmology, 2019, 43, 3-9.	0.4	9

#	ARTICLE	IF	CITATIONS
37	General information for patients and carers considering haematopoietic stem cell transplantation (HSCT) for severe autoimmune diseases (ADs): A position statement from the EBMT Autoimmune Diseases Working Party (ADWP), the EBMT Nurses Group, the EBMT Patient, Family and Donor Committee and the Joint Accreditation Committee of ISCT and EBMT (JACIE). <i>Bone Marrow Transplantation</i> , 2019, 54, 933-949.	1.3	25
38	Autologous Haematopoietic Stem Cell Transplantation in Multiple Sclerosis: a Review of Current Literature and Future Directions for Transplant Haematologists and Oncologists. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 127-135.	1.2	21
39	Autologous haematopoietic stem cell therapy for multiple sclerosis: a review for supportive care clinicians on behalf of the Autoimmune Diseases Working Party of the European Society for Blood and Marrow Transplantation. <i>Current Opinion in Supportive and Palliative Care</i> , 2019, 13, 394-401.	0.5	10
40	Capecitabine leukoencephalopathy. <i>Practical Neurology</i> , 2019, 19, 270-271.	0.5	5
41	Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 165.	3.8	208
42	Animal models of multiple sclerosis: From rodents to zebrafish. <i>Multiple Sclerosis Journal</i> , 2019, 25, 306-324.	1.4	95
43	BEAM Vs Cyclophosphamide-Based Conditioning Regimen in Aggressive Multiple Sclerosis: A Retrospective Analysis of European Blood and Marrow Transplantation Society. <i>Blood</i> , 2019, 134, 3313-3313.	0.6	1
44	Effects of ATX-MS-1467 immunotherapy over 16 weeks in relapsing multiple sclerosis. <i>Neurology</i> , 2018, 90, e955-e962.	1.5	66
45	Novel genotype-phenotype and MRI correlations in a large cohort of patients with <i>SPG7</i> mutations. <i>Neurology: Genetics</i> , 2018, 4, e279.	0.9	44
46	Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis. <i>BMJ Open</i> , 2018, 8, e021944.	0.8	43
47	Characterisation of tissue-type metabolic content in secondary progressive multiple sclerosis: a magnetic resonance spectroscopic imaging study. <i>Journal of Neurology</i> , 2018, 265, 1795-1802.	1.8	7
48	Epstein Barr virus shedding in multiple sclerosis: Similar frequencies of EBV in saliva across separate patient cohorts. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 25, 197-199.	0.9	14
49	Autologous haematopoietic stem cell transplantation (aHSCT) for severe resistant autoimmune and inflammatory diseases – a guide for the generalist. <i>Clinical Medicine</i> , 2018, 18, 329-334.	0.8	34
50	MiR-126 and miR-126* regulate shear-resistant firm leukocyte adhesion to human brain endothelium. <i>Scientific Reports</i> , 2017, 7, 45284.	1.6	50
51	Blogs cannot separate wheat from chaff. <i>Science</i> , 2017, 358, 602-602.	6.0	0
52	Qualitative Investigation of Exercise Perceptions and Experiences in People With Multiple Sclerosis Before, During, and After Participation in a Personally Tailored Exercise Program. <i>Archives of Physical Medicine and Rehabilitation</i> , 2017, 98, 2520-2525.	0.5	16
53	Autologous hematopoietic cell transplantation in multiple sclerosis. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 77-86.	1.4	11
54	PO152 – Alemtuzumab efficacy in patients with relapse after course 1. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, A53.1-A53.	0.9	0

#	ARTICLE	IF	CITATIONS
55	MicroRNA-155 contributes to shear-resistant leukocyte adhesion to human brain endothelium in vitro. <i>Fluids and Barriers of the CNS</i> , 2016, 13, 8.	2.4	39
56	Gene expression profiling of the astrocyte transcriptome in multiple sclerosis normal appearing white matter reveals a neuroprotective role. <i>Journal of Neuroimmunology</i> , 2016, 299, 139-146.	1.1	44
57	Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial. <i>Lancet Neurology</i> , The, 2016, 15, 259-269.	4.9	168
58	Participant recruitment into a randomised controlled trial of exercise therapy for people with multiple sclerosis. <i>Trials</i> , 2015, 16, 468.	0.7	17
59	We can compare the relative efficacy of multiple sclerosis medications by examining the results of independent clinical trials: Yes. <i>Multiple Sclerosis Journal</i> , 2015, 21, 35-36.	1.4	1
60	Cognitive rehabilitation in multiple sclerosis: A systematic review. <i>Journal of the Neurological Sciences</i> , 2015, 354, 1-9.	0.3	105
61	PTEN Depletion Decreases Disease Severity and Modestly Prolongs Survival in a Mouse Model of Spinal Muscular Atrophy. <i>Molecular Therapy</i> , 2015, 23, 270-277.	3.7	47
62	Brain Endothelial miR-146a Negatively Modulates T-Cell Adhesion through Repressing Multiple Targets to Inhibit NF- κ B Activation. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2015, 35, 412-423.	2.4	76
63	THERAPEUTIC PLASMAPHERESIS: THE SHEFFIELD EXPERIENCE. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, e4.75-e4.	0.9	0
64	PTEN: A molecular target for neurodegenerative disorders. <i>Translational Neuroscience</i> , 2012, 3, .	0.7	13
65	Citrullination of CNS proteins in the pathogenesis of multiple sclerosis. <i>Future Neurology</i> , 2011, 6, 521-530.	0.9	1